重组人内皮抑素恩度不同给药途径联合TP方案治疗进展期卵巢癌的临床研究
|
摘要
目的分析研究重组人内皮抑素恩度不同给药途径联合TP方案治疗进展期卵巢癌的应用效果,为进展期卵巢癌患者的临床治疗提供新的思路及理论支持。方法抽取2012年1月至2015年1月我院接收的62例进展期卵巢癌患者作为研究对象,根据给药途径不同分为观察组与对照组,各31例,对照组采用静脉滴注恩度联合TP方案治疗,观察组采用持续静脉泵注入恩度联合TP方案治疗,对比观察两组患者治疗有效率及治疗前后血清血管内皮生长因子水平变化情况。结果观察组治疗总有效率为80.6%,对照组为74.2%,两组相比差异无统计学意义(P>0.05);治疗前两组患者血清血管内皮生长因子水平相比无显著差异(P>0.05),经治疗,观察组优于对照组,差异显著(P<0.05)。结论持续静脉泵注入恩度联合TP方案治疗进展期卵巢癌患者效果更加显著,可有效降低血清血管内皮生长因子水平,从而控制肿瘤生长速度,提高治疗效果。
Objective To analyze the effect of recombinant human endostatin endostatin different routes of administration joint application effect of TP regimen for advanced ovarian cancer,to provide new ideas and theoretical support for the clinical treatment of advanced ovarian cancer patients. Methods 62 cases of advanced ovarian cancer patients from January 2012 to January 2015 in our hospital were selected as the research object, according to route of administration they were divided into observation group and control group,31 cases in each group. The control group was given intravenous infusion of Endostar combined with TP Regimen in the treatment, the observation group was treated with continuous intravenous infusion of Endostar combined with TP Regimen in the treatment. The effective rate of treatment before and after treatment and the changes of serum vascular endothelial growth factor level in patients of two groups were compared. Results The total effective rate of the observation group was 80.6%, the control group was 74.2%, and there was no significant difference between the two groups(P>0.05);There was no significant difference in serum vascular endothelial growth factor between the two groups before treatment(P >0.05). After treatment, the observation group was better than the control group, and the difference was significant(P<0.05). Conclusion Continuous pump intravenous injected Endostar combined with TP Regimen in the treatment of advanced ovarian cancer patients the effect is more obvious, can effectively reduce the serum levels of vascular endothelial growth factor level to control tumor growth rate, improve the therapeutic effect.
Objective To analyze the effect of recombinant human endostatin endostatin different routes of administration joint application effect of TP regimen for advanced ovarian cancer,to provide new ideas and theoretical support for the clinical treatment of advanced ovarian cancer patients. Methods 62 cases of advanced ovarian cancer patients from January 2012 to January 2015 in our hospital were selected as the research object, according to route of administration they were divided into observation group and control group,31 cases in each group. The control group was given intravenous infusion of Endostar combined with TP Regimen in the treatment, the observation group was treated with continuous intravenous infusion of Endostar combined with TP Regimen in the treatment. The effective rate of treatment before and after treatment and the changes of serum vascular endothelial growth factor level in patients of two groups were compared. Results The total effective rate of the observation group was 80.6%, the control group was 74.2%, and there was no significant difference between the two groups(P>0.05);There was no significant difference in serum vascular endothelial growth factor between the two groups before treatment(P >0.05). After treatment, the observation group was better than the control group, and the difference was significant(P<0.05). Conclusion Continuous pump intravenous injected Endostar combined with TP Regimen in the treatment of advanced ovarian cancer patients the effect is more obvious, can effectively reduce the serum levels of vascular endothelial growth factor level to control tumor growth rate, improve the therapeutic effect.
引文
[1]唐名杰,王世坤,熊文明,等.恩度联合GEMOX方案治疗复发或难治性卵巢癌的临床观察[J].中国癌症防治杂志,2015,7(5):360-363.
[2]齐元玲,任海朋,于杰,等.重组人血管内皮抑制素联合紫杉醇和卡铂方案与TP方案治疗晚期卵巢癌的随机对照研究[J].中国继续医学教育,2015,7(22):149-150.
[3]刘国华.重组人血管内皮抑制素联合TP方案治疗卵巢癌的近期疗效[J].中外医学研究,2014,12(13):3-4.
[4]满莉,周立中,董宇洋.重组人血管内皮抑素联合化疗一线治疗上皮性卵巢癌的临床观察[J].中国当代医药,2013,20(27):45-47.
[5]张淼慈,李萍,哈敏文.重组人血管内皮抑素联合吉西他滨治疗铂类耐药复发卵巢癌的临床观察[J].山东大学学报(医学版),2014,52(11):55-59.
[6]张隆,刘会娟,贺丽亚,等.重组人血管内皮抑素联合紫杉醇脂质体卡铂方案治疗晚期卵巢癌的临床观察[J].河北医药,2015,37(3):358-360.
[2]齐元玲,任海朋,于杰,等.重组人血管内皮抑制素联合紫杉醇和卡铂方案与TP方案治疗晚期卵巢癌的随机对照研究[J].中国继续医学教育,2015,7(22):149-150.
[3]刘国华.重组人血管内皮抑制素联合TP方案治疗卵巢癌的近期疗效[J].中外医学研究,2014,12(13):3-4.
[4]满莉,周立中,董宇洋.重组人血管内皮抑素联合化疗一线治疗上皮性卵巢癌的临床观察[J].中国当代医药,2013,20(27):45-47.
[5]张淼慈,李萍,哈敏文.重组人血管内皮抑素联合吉西他滨治疗铂类耐药复发卵巢癌的临床观察[J].山东大学学报(医学版),2014,52(11):55-59.
[6]张隆,刘会娟,贺丽亚,等.重组人血管内皮抑素联合紫杉醇脂质体卡铂方案治疗晚期卵巢癌的临床观察[J].河北医药,2015,37(3):358-360.